Drug updated on 4/18/2024
| Dosage Form | Injection (intramuscular; 50 units/vial, 100 units/vial) |
| Drug Class | Acetylcholine release inhibitors and neuromuscular blocking agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Summary
- DaxibotulinumtoxinA-lanm (Daxxify) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
- A single study compared Daxxify's safety and efficacy against four other botulinum toxin type A formulations: OnabotulinumtoxinA, AbobotulinumtoxinA, IncobotulinumtoxinA, and PrabotulinumtoxinA.
- The network meta-analysis revealed that all botulinum toxin type A formulations were significantly more effective than placebo. However, DaxibotulinumtoxinA (Daxxify) significantly increased the proportion of subjects achieving at least a 1-point improvement in glabellar line severity score compared to other botulinum toxin type A formulations.
- In terms of safety profile comparison among all botulinum toxin type A treatments, including Daxxify, there were no significant differences regarding incidence rates of any adverse events related to treatment or drug, indicating a comparable level of tolerance across these drugs.
- The findings focus on the general adult population suffering from moderate to severe glabellar lines due to corrugator/procerus muscle activity.
- Based on the information provided by this study, while maintaining a similar safety profile as existing treatments, DaxibotulinumtoxinA (Daxxify) may be more effective when treating glabellar lines among adults.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Daxxify (daxibotulinumtoxinA-lanm) Prescribing Information. | 2022 | Revance Therapeutics Inc., Newark, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of botulinum toxin type A for treatment of glabellar lines: A network meta-analysis of randomized controlled trials. | 2023 | Aesthetic Plastic Surgery |